Effectiveness of Continuous Dopaminergic Therapies in Parkinson’s Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics
Journal of Parkinson’s Disease · 23.07.2024 · 14 (5) · 925-939
DOI: 10.3233/jpd-230372 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 31.05.2024. Verfasst von Alexandre Demailly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Université Lille, Lille, France. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Antiparkinson Agents. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Parkinson’s disease (PD) is characterized by striatal dopamine deficiency. Since dopamine cannot cross the digestive and blood-brain barriers, its precursor, levodopa (L-DOPA), remains the mainstay of treatment. However, the significant pharmacokinetic (Pk) and pharmacodynamic (Pd) limitations of L-DOPA, combined with the severity of PD, may trigger motor and non-motor complications, for which continuous dopaminergic delivery therapies have been developed.
Objective
The aim of this study was to review the literature on the Pk/Pd limitations of L-DOPA and how current treatments of continuous dopaminergic administration ameliorate these problems, in order to identify the need for new therapeutic avenues.
Methods
A comprehensive literature search was carried out using PubMed and 75 articles were initially extracted. Following independent screening by two reviewers and consideration of eligibility, 10 articles were chosen for further analysis. Information concerning the Pk/Pd of L-DOPA was classified for each article.
Results
Pk/Pd problems notably include: (i) restricted digestive and cerebral absorption; (ii) unnecessary peripheral distribution; (iii) short half-life; (iv) age- and PD-induced decline of central aromatic L-amino acid decarboxylase; (v) misdistribution in many cells; and (vii) pulsatile stimulation of dopaminergic receptors. Current treatments only slightly ameliorate some of these problems.
Conclusions
Many Pk/Pd constraints are not resolved by existing continuous dopaminergic delivery therapies. This highlights the significant gap between these treatments and the ideal of continuous dopaminergic stimulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Lille, Lille, France.
- Neurology Department & Parkinson's Disease Centre of Excellence, INSERM, CHU Lille, U1172 - Degenerative & Vascular Cognitive Disorders, LilNCog, Lille Neuroscience & Cognition, LICEND, NS-Park Network, Lille, France.
- Medical Pharmacology Department, CHU Lille, Lille, France.
Zitieren
APA
Demailly, A., Moreau, C., & Devos, D. (2024). Effectiveness of Continuous Dopaminergic Therapies in Parkinson’s Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics. Journal of Parkinson’s Disease, 14(5), 925-939. https://doi.org/10.3233/jpd-230372
Vancouver
Demailly A, Moreau C, Devos D. Effectiveness of Continuous Dopaminergic Therapies in Parkinson’s Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics. Journal of Parkinson’s Disease. 2024;14(5):925-939. doi:10.3233/jpd-230372
BibTeX
@article{Demailly2024,
author = {Demailly, Alexandre and Moreau, Caroline and Devos, David},
title = {Effectiveness of Continuous Dopaminergic Therapies in Parkinson’s Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics},
journal = {Journal of Parkinson’s Disease},
year = {2024},
volume = {14},
number = {5},
pages = {925--939},
doi = {10.3233/jpd-230372}
}
EUVIMED